You are here

Article Text

Article menu
Download PDFPDF
Short report
Thermolabile methylenetetrahydrofolate reductase gene and the risk of cognitive impairment in those over 85
  1. J Gusseklooa,
  2. B T Heijmansb,
  3. P E Slagboomb,
  4. A M Lagaaya,
  5. D L Knooka,b,
  6. R G J Westendorpa,c
  1. aSection of Gerontology and Geriatrics, Department of General Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands, bGaubius Laboratory, TNO Prevention and Health, Leiden, The Netherlands, cDepartment of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
  1. Dr Jacobijn Gussekloo, Section of Gerontology and Geriatrics, Department of General Internal Medicine, Leiden University Medical Centre, PO box 9600, 2300 RC Leiden, the Netherlands. Telephone 0031 71 5266640; fax 0031 71 5248159; emailLeiden85plus{at}aig.ozl.nl

Abstract

OBJECTIVES Previous reports have shown raised plasma concentrations of homocysteine in older persons with cognitive impairment. This may be caused by environmental and genetic factors. The relation between cognitive function and a commonala/val mutation in the methylenetetrahydrofolate reductase (MTHFR) gene was studied in those over 85. Homozygous carriers of this mutation are characterised by a lifelong exposure to moderately raised plasma concentrations of homocysteine.

METHODS In the Leiden 85-plus Study, a population based study of persons aged 85 years and over, the score on the mini mental state examination (MMSE) and the presence of dementia dependent on the MTHFR genotypes were compared in 641 participants (456 women, 185 men) at baseline. In addition, the association between the MTHFR genotype and cognitive decline was studied by re-examining cognitive function of 172 participants without dementia at baseline after a median follow up of 4.0 years.

RESULTS At baseline, carriers of the ala/ala genotype had a median MMSE score of 27 points (interquartile range (IQR) 21.5–29), for the ala/val genotype it was 26 points (IQR 20–29), and for the val/val genotype it was 27 points (IQR 20–28.3) (p=0.3). The prevalence of dementia was also not significantly different for the various genotypes (ala/ala 22%,ala/val 28%,val/val 27%; p=0.4). None of the carriers of the val/val genotype without cognitive impairment at baseline developed dementia during the follow up.

CONCLUSIONS Although previous studies have shown that older persons with cognitive impairment have raised plasma concentrations of homocysteine, homozygosity for the ala toval mutation in the MTHFR gene is not a genetic risk factor for cognitive impairment in persons aged 85 years and over.

  • methylenetetrahydrofolate reductase gene
  • cognitive impairment

https://doi.org/10.1136/jnnp.67.4.535

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes